Fig. 4

Kras mutation in CRC suppressed AMPK activation to stabilize Mcl-1. a Western blot of indicated proteins in DLD1 WT (+/−) and Kras mutation (G13D/−) cells treated with 5 nM Cet for indicated time points. b DLD1 WT (+/−) transfected with control or AMPK shRNA were treated with 5 nM Cet for 48 h. The expression of Mcl-1 and PUMA was analyzed. c The Mcl-1 and PUMA expression in DLD1 Kras mutation cells treated with 5 μM Met in combined with 5 nM Cet for 48 h. d DLD1 Kras mutated cells transfected with control or Mcl-1 shRNA were treated with 5 nM Cet for 48 h. The expression of indicated was analyzed. e The apoptosis of DLD1 Kras mutated cells treated as in (d). f DLD1 Kras mutated cells transfected with control or Mcl-1 plasmids were treated with 5 nM Cet in combined with 5 μM Met for 48 h. The expression of Mcl-1 and caspase-3 (C3) was analyzed. g The apoptosis of DLD1 Kras mutated cells treated as in (f). Each experiment was repeated for 3 times. *, p < 0.05; **, p < 0.01; ***, p < 0.001